antitumor activity. Jahrestagung der American Association for Cancer 
      Research (AACR) 2011, Abstract 1347; Cancer Research 2011, 71 (8 
      Supplement) 
 
   7. ClinicalTrials.gov-Identifier: NCT03250299 
 
   8. ClinicalTrials.gov-Identifier: NCT02895360 
 
   9. A. Sharmq, A. Broggini-Tenzer, V. Vuong et al. The novel microtubule 
      targeting agent BAL101553 in combination with radiotherapy in 
      treatment-refractory tumor models. Radiotherapy Oncology 2017 (124), 
      433-438 
 
  10. G. E. Duran, H. Lane, F. Bachmann et al. In vitro activity of the novel 
      tubulin active agent BAL27862 in MDR1(+) and MDR1(-) human breast and 
      ovarian cancer variants selected for resistance to taxanes. Jahrestagung 
      der American Association for Cancer Research (AACR) 2010, Abstract 4412; 
      Cancer Research 2010, 70 (8 Supplement) 
 
  11. F. Bachmann, K. Burger, G. E. Duran et al. BAL101553 (prodrug of 
      BAL27862): A unique microtubule destabilizer active against drug 
      refractory breast cancers alone and in combination with trastuzumab. 
      Jahrestagung der American Association for Cancer Research (AACR) 2014, 
      Abstract 831; Cancer Research 2014, 74 (19 Supplement) 
 
  12. A. Schmitt-Hoffmann, D. Klauer, K. Gebhardt et al. BAL27862: a unique 
      microtubule-targeted agent with a potential for the treatment of human 
      brain tumors. AACR-NCI-EORTC-Konferenz 2009, Abstract C233; Molecular 
      Cancer Therapeutics 2009, 8 (12 Supplement) 
 
  13. A. C. Mladek, J. L. Pokorny, H. Lane et al. The novel tubulin-binding 
      'tumor checkpoint controller' BAL101553 has anti-cancer activity alone 
      and in combination treatments across a panel of GBM patient-derived 
      xenografts. Jahrestagung der American Association for Cancer Research 
      (AACR) 2016, Abstract 4781; Cancer Research 2016, 76 (14 Supplement) 
 
  14. A. E. Prota, F. Danel, F. Bachmann et al. The novel 
      microtubule-destabilizing drug BAL27862 binds to the colchicine site of 
      tubulin with distinct effects on microtubule organization. Journal of 
      Molecular Biology 2014 (426), 1848-1860 
 
  15. F. Bachmann, K. Burger, H. Lane. BAL101553 (prodrug of BAL27862): the 
      spindle assembly checkpoint is required for anticancer activity. 
      Jahrestagung der American Association for Cancer Research (AACR) 2015, 
      Abstract 3789; Cancer Research 2015, 75 (15 Supplement) 
 
   Anhang 
 
 
   -- Pressemitteilung (PDF) 
      https://ml-eu.globenewswire.com/Resource/Download/ab1a57b7-9c28-4b82-8d3d-f90656dfdc6a

(END) Dow Jones Newswires

June 07, 2021 01:15 ET (05:15 GMT)